EXP01 Dermatomyositis 2026: Modern Approaches to Phenotyping, Malignancy Surveillance, and Therapeutic Innovation
DESCRIPTION
Many clinicians use a one-size-fits-all approach to dermatomyositis, with inconsistent malignancy screening and delayed adoption of targeted therapies. This session provides an actionable framework for patient phenotyping, cancer surveillance, screening for systemic involvement, and modern treatment selection. Screening strategies for systemic involvement and malignancy in dermatomyositis, as recommended by international groups such as EULAR/ACR and IMACS, will be distilled into practical, easy-to-digest guidance for dermatologists. Through case-based discussion, dermatologists will gain practical strategies to personalize care, improve outcomes, and reduce reliance on long-term corticosteroids. The novel therapies discussed will include biologics, Janus Kinase(JAK) inhibitors, and treatments targeting interferon (IFN) pathways.
This session is not certified for AMA PRA Category 1 CME Credit.
LEARNING OBJECTIVES
Differentiate dermatomyositis subtypes using clinical and serologic phenotyping.
Apply current evidence-based guidelines for malignancy risk stratification and screening in dermatomyositis
Incorporate novel therapies—including biologics and JAK inhibitors—into the management ladder of dermatomyositis
SCHEDULE
10:00 AM
Modern Approaches to Phenotyping, Malignancy Surveillance, and Therapeutic Innovation
10:22 AM
Question and Answer
DIRECTOR
Urmi Khanna, MD, FAAD
Department of Dermatology, Dartmouth Hitchcock Medical Center
SPEAKER
Dorothea Torti Barton, MD, FAAD
Dartmouth Health and Geisel School of Medicine at Dartmouth
DISCLOSURES
Dorothea Torti Barton, MD, FAAD
Priovant Therapeutics – Advisory Board(Honoraria);
Urmi Khanna, MD, FAAD
No financial relationships exist with ineligible companies.